FY2027 Earnings Forecast for AGIO Issued By HC Wainwright

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Analysts at HC Wainwright increased their FY2027 earnings estimates for Agios Pharmaceuticals in a research note issued on Monday, April 20th. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will post earnings per share of ($5.46) for the year, up from their prior forecast of ($5.48). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.58) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ FY2028 earnings at ($4.64) EPS, FY2029 earnings at ($2.68) EPS and FY2030 earnings at $2.41 EPS.

Other analysts have also recently issued research reports about the stock. Wall Street Zen upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. Leerink Partners increased their price objective on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, December 26th. Bank of America dropped their price objective on shares of Agios Pharmaceuticals from $44.00 to $41.00 and set a “buy” rating on the stock in a research report on Tuesday. Citigroup increased their price objective on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Finally, Truist Financial increased their price objective on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, December 24th. Six equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $41.78.

Agios Pharmaceuticals Price Performance

Shares of AGIO stock opened at $26.72 on Thursday. The stock has a market cap of $1.57 billion, a P/E ratio of -3.76 and a beta of 0.79. The company has a fifty day moving average price of $30.10 and a two-hundred day moving average price of $31.61. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, insider James William Burns sold 3,280 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total transaction of $113,848.80. Following the transaction, the insider directly owned 49,306 shares of the company’s stock, valued at approximately $1,711,411.26. This trade represents a 6.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Cecilia Jones sold 3,141 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $109,024.11. Following the transaction, the chief financial officer directly owned 54,998 shares in the company, valued at approximately $1,908,980.58. This represents a 5.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 15,582 shares of company stock valued at $520,405 in the last quarter. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Creative Planning boosted its stake in shares of Agios Pharmaceuticals by 2.2% in the third quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company’s stock valued at $527,000 after buying an additional 280 shares during the period. Assetmark Inc. grew its position in Agios Pharmaceuticals by 37.9% during the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 362 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Agios Pharmaceuticals by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock worth $4,393,000 after buying an additional 512 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Agios Pharmaceuticals by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 588 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its position in Agios Pharmaceuticals by 3.4% during the third quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock worth $796,000 after buying an additional 662 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.